Related Experiment Videos

High-dose methylprednisolone and acetazolamide for visual loss in pseudotumor cerebri

G T Liu1, J S Glaser, N J Schatz

  • 1Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Florida.

Insights

Intravenous methylprednisolone effectively treated severe vision loss in pseudotumor cerebri patients. Persistent papilledema despite treatment may necessitate optic nerve sheath fenestration.

Area of Science:

  • Ophthalmology
  • Neurology

Background:

  • Pseudotumor cerebri (idiopathic intracranial hypertension) can cause severe visual loss.
  • High-grade papilledema is a hallmark of this condition.
  • Prompt treatment is crucial to prevent irreversible vision damage.

Observation:

  • Four patients with acute, severe visual loss due to pseudotumor cerebri were treated.
  • The treatment regimen included intravenous methylprednisolone, acetazolamide, and ranitidine.
  • Ocular findings included high-grade disk edema, macular detachment, macular star, and retinal artery occlusion.

Findings:

  • Three of four patients showed rapid and sustained improvement in visual acuity, visual fields, and papilledema.
  • One patient did not respond to medical treatment and required optic nerve sheath fenestration.
  • Transient acne was the only reported side effect.

Implications:

  • This treatment regimen is a safe and effective option for acute, severe visual loss in pseudotumor cerebri.
  • Lack of immediate response to this therapy suggests the need for surgical intervention, such as optic nerve sheath fenestration.
  • Early intervention is key to preserving vision in patients with pseudotumor cerebri.

Related Concept Videos